Cargando…

Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in Children and Adolescents With Inflammatory Bowel Disease

Background. Anemia is common in inflammatory bowel disease (IBD). Oral iron is widely used but efficacy can be reduced by poor compliance and insufficient absorption. Intravenous iron is safe and effective in adults but is not well studied in children. Purpose. To assess safety and efficacy of intra...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabe, Ramy, Vatsayan, Anant, Mahran, Amr, Khalili, Ali S., Ahuja, Sanjay, Sferra, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700850/
https://www.ncbi.nlm.nih.gov/pubmed/31453270
http://dx.doi.org/10.1177/2333794X19870981
_version_ 1783444946034884608
author Sabe, Ramy
Vatsayan, Anant
Mahran, Amr
Khalili, Ali S.
Ahuja, Sanjay
Sferra, Thomas J.
author_facet Sabe, Ramy
Vatsayan, Anant
Mahran, Amr
Khalili, Ali S.
Ahuja, Sanjay
Sferra, Thomas J.
author_sort Sabe, Ramy
collection PubMed
description Background. Anemia is common in inflammatory bowel disease (IBD). Oral iron is widely used but efficacy can be reduced by poor compliance and insufficient absorption. Intravenous iron is safe and effective in adults but is not well studied in children. Purpose. To assess safety and efficacy of intravenous iron sucrose (IVIS) in children with IBD. Methods. We reviewed medical records of IBD patients <22 years of age who received IVIS at our institution between 2009 and 2014. Anemia was defined as hemoglobin (Hgb) level below normal for age and gender and iron-deficiency anemia as serum iron studies and red cell mean corpuscular volume below normal ranges. Each IVIS infusion was evaluated for safety. Efficacy was defined as ≥2 g/dL increase in Hgb ≤12 weeks from IVIS initiation. Results. We identified 88 patients (Crohn’s disease, n = 52; ulcerative colitis, n = 33; IBD-unclassified, n = 3) who underwent 329 IVIS infusions over 121 courses. No patient developed anaphylaxis. Six patients developed minor adverse reactions. Of the 121 IVIS courses, 80 were included in the efficacy evaluation. There was a significant rise in Hgb (mean 9.1 ±1.4 to 11.9 ± 1.8 g/dL; P < .0001, paired t test). Overall, 58.7% (47/80 courses) resulted in goal Hgb increase. Conclusions. IVIS is safe and effective in treating iron-deficiency anemia in pediatric IBD. There were only minor adverse events, and the observed rise in Hgb was clinically significant, with the majority achieving goal Hgb.
format Online
Article
Text
id pubmed-6700850
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-67008502019-08-26 Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in Children and Adolescents With Inflammatory Bowel Disease Sabe, Ramy Vatsayan, Anant Mahran, Amr Khalili, Ali S. Ahuja, Sanjay Sferra, Thomas J. Glob Pediatr Health Original Article Background. Anemia is common in inflammatory bowel disease (IBD). Oral iron is widely used but efficacy can be reduced by poor compliance and insufficient absorption. Intravenous iron is safe and effective in adults but is not well studied in children. Purpose. To assess safety and efficacy of intravenous iron sucrose (IVIS) in children with IBD. Methods. We reviewed medical records of IBD patients <22 years of age who received IVIS at our institution between 2009 and 2014. Anemia was defined as hemoglobin (Hgb) level below normal for age and gender and iron-deficiency anemia as serum iron studies and red cell mean corpuscular volume below normal ranges. Each IVIS infusion was evaluated for safety. Efficacy was defined as ≥2 g/dL increase in Hgb ≤12 weeks from IVIS initiation. Results. We identified 88 patients (Crohn’s disease, n = 52; ulcerative colitis, n = 33; IBD-unclassified, n = 3) who underwent 329 IVIS infusions over 121 courses. No patient developed anaphylaxis. Six patients developed minor adverse reactions. Of the 121 IVIS courses, 80 were included in the efficacy evaluation. There was a significant rise in Hgb (mean 9.1 ±1.4 to 11.9 ± 1.8 g/dL; P < .0001, paired t test). Overall, 58.7% (47/80 courses) resulted in goal Hgb increase. Conclusions. IVIS is safe and effective in treating iron-deficiency anemia in pediatric IBD. There were only minor adverse events, and the observed rise in Hgb was clinically significant, with the majority achieving goal Hgb. SAGE Publications 2019-08-18 /pmc/articles/PMC6700850/ /pubmed/31453270 http://dx.doi.org/10.1177/2333794X19870981 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Sabe, Ramy
Vatsayan, Anant
Mahran, Amr
Khalili, Ali S.
Ahuja, Sanjay
Sferra, Thomas J.
Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in Children and Adolescents With Inflammatory Bowel Disease
title Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in Children and Adolescents With Inflammatory Bowel Disease
title_full Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in Children and Adolescents With Inflammatory Bowel Disease
title_fullStr Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in Children and Adolescents With Inflammatory Bowel Disease
title_full_unstemmed Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in Children and Adolescents With Inflammatory Bowel Disease
title_short Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in Children and Adolescents With Inflammatory Bowel Disease
title_sort safety and efficacy of intravenous iron sucrose for iron-deficiency anemia in children and adolescents with inflammatory bowel disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700850/
https://www.ncbi.nlm.nih.gov/pubmed/31453270
http://dx.doi.org/10.1177/2333794X19870981
work_keys_str_mv AT saberamy safetyandefficacyofintravenousironsucroseforirondeficiencyanemiainchildrenandadolescentswithinflammatoryboweldisease
AT vatsayananant safetyandefficacyofintravenousironsucroseforirondeficiencyanemiainchildrenandadolescentswithinflammatoryboweldisease
AT mahranamr safetyandefficacyofintravenousironsucroseforirondeficiencyanemiainchildrenandadolescentswithinflammatoryboweldisease
AT khalilialis safetyandefficacyofintravenousironsucroseforirondeficiencyanemiainchildrenandadolescentswithinflammatoryboweldisease
AT ahujasanjay safetyandefficacyofintravenousironsucroseforirondeficiencyanemiainchildrenandadolescentswithinflammatoryboweldisease
AT sferrathomasj safetyandefficacyofintravenousironsucroseforirondeficiencyanemiainchildrenandadolescentswithinflammatoryboweldisease